Editas Medicine Inc. | Ownership
Companies that own Editas Medicine Inc.
The Vanguard Group, Inc.
3,496,812
7.34%
540,772
0%
06/30/2018
BlackRock Fund Advisors
3,187,545
6.69%
524,768
0.01%
06/30/2018
Fidelity Management & Research Co.
2,827,040
5.93%
-422,122
0.01%
06/30/2018
SSgA Funds Management, Inc.
2,595,883
5.45%
201,541
0.01%
06/30/2018
Capital Research & Management Co. (World Investors)
2,184,000
4.58%
0
0.01%
06/30/2018
ARK Investment Management LLC
2,181,572
4.58%
561,364
2.36%
06/30/2018
Morgan Stanley Investment Management, Inc.
1,293,303
2.71%
21,232
0.06%
06/30/2018
Deerfield Management Company LP
1,158,841
2.43%
0
1.09%
06/30/2018
Viking Global Investors LP
931,401
1.95%
-103,903
0.16%
06/30/2018
T. Rowe Price Associates, Inc.
783,905
1.64%
-108,454
0%
06/30/2018
| Address |
11 Hurley Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.editasmedicine.com |
| Updated |
07/08/2019 |
| Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. |
